Literature DB >> 10812003

1,25-dihydroxyvitamin D3 synthetic analogs inhibit spontaneous metastases in a 1,2-dimethylhydrazine-induced colon carcinogenesis model.

S R Evans1, E I Shchepotin, H Young, J Rochon, M Uskokovic, I B Shchepotin.   

Abstract

In order to substantiate the role of vitamin D applicability for the prevention of colon cancer and its spontaneous metastases, the effect of 1,25-dihydroxyvitamin D3 and its synthetic analogs, 1, 25-dihydroxy-16,23Z-diene-26,27-hexafluoro-D3 (Ro 25-5317) and 1, 25-dihydroxy-16,23E-diene-26,27-hexafluoro-19-nor-D3 (Ro 25-9022), have been evaluated in a 1,2-dimethylhydrazine (DMH)-induced colon carcinogenesis model in Sprague-Dawley rats. In animals maintained on 2.75 nmol/kg 1,25-dihydroxyvitamin D3 diet no statistical difference was seen in tumor incidence when compared with control while in animals on 3.0 nmol/kg 1,25-dihydroxyvitamin D3 diet, the incidence of tumors was significantly lower. In animals maintained on 3.0 nmol/kg Ro 25-5317 diet also no statistical difference was seen in tumor incidence compared with control while in animals on 3. 5 nmol/kg Ro 25-5317 diet the incidence of tumors was significantly lower. The incidence of tumors in the group of animals maintained on 3.0 nmol/kg and 3.5 nmol/kg Ro 25-9022 was significantly lower, at 32.1% and 27.6% respectively, compared to control. In the two groups of animals maintained on the 1,25-dihydroxyvitamin D3 diet no significant difference in the incidence of metastasis was seen. In the group of animals maintained on 3.0 nmol/kg Ro 25-5317 diet only regional metastases were seen. However, no metastases developed in the rats on 3.5 nmol/kg Ro 25-5317 diet. After administration of 3.0 nmol/kg Ro 25-9022 diet, metastases developed in a significantly less number of animals while no metastases occurred in the rats maintained on the 3.5 nmol/kg Ro 25-9022 diet. The above studies will provide a scientific basis for the progression into further clinical trials in the treatment, and/or chemoprevention of human colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10812003     DOI: 10.3892/ijo.16.6.1249

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  18 in total

1.  Vitamin D status in patients with stage IV colorectal cancer: findings from Intergroup trial N9741.

Authors:  Kimmie Ng; Daniel J Sargent; Richard M Goldberg; Jeffrey A Meyerhardt; Erin M Green; Henry C Pitot; Bruce W Hollis; Michael N Pollak; Charles S Fuchs
Journal:  J Clin Oncol       Date:  2011-03-21       Impact factor: 44.544

2.  Circulating levels of vitamin D and colon and rectal cancer: the Physicians' Health Study and a meta-analysis of prospective studies.

Authors:  Jung Eun Lee; Haojie Li; Andrew T Chan; Bruce W Hollis; I-Min Lee; Meir J Stampfer; Kana Wu; Edward Giovannucci; Jing Ma
Journal:  Cancer Prev Res (Phila)       Date:  2011-03-23

3.  Dietary supplementation with isolated soy protein reduces metastasis of mammary carcinoma cells in mice.

Authors:  Lin Yan; Donghua Li; John A Yee
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

4.  Influence of genetic variation in the vitamin D pathway on plasma 25-hydroxyvitamin D3 levels and survival among patients with metastatic colorectal cancer.

Authors:  Chen Yuan; Lindsay Renfro; Pratibha B Ambadwar; Fang-Shu Ou; Howard L McLeod; Federico Innocenti; Jeffrey A Meyerhardt; Brian M Wolpin; Richard M Goldberg; Axel Grothey; Charles S Fuchs; Kimmie Ng
Journal:  Cancer Causes Control       Date:  2019-05-18       Impact factor: 2.506

5.  Prevalence of serum vitamin D deficiency and insufficiency in cancer: Review of the epidemiological literature.

Authors:  Digant Gupta; Pankaj G Vashi; Kristen Trukova; Christopher G Lis; Carolyn A Lammersfeld
Journal:  Exp Ther Med       Date:  2011-01-20       Impact factor: 2.447

6.  Vitamin D Levels in Patients with Colorectal Cancer Before and After Treatment Initiation.

Authors:  Marissa B Savoie; Alan Paciorek; Li Zhang; Erin L Van Blarigan; Nilli Sommovilla; Donald Abrams; Chloe E Atreya; Emily K Bergsland; Hueylan Chern; Robin K Kelley; Andrew Ko; Angela Laffan; Ankit Sarin; Madhulika G Varma; Alan P Venook; Katherine Van Loon
Journal:  J Gastrointest Cancer       Date:  2019-12

7.  Plasma 25-Hydroxyvitamin D Levels and Survival in Patients with Advanced or Metastatic Colorectal Cancer: Findings from CALGB/SWOG 80405 (Alliance).

Authors:  Jeffrey A Meyerhardt; Kimmie Ng; Chen Yuan; Kaori Sato; Bruce W Hollis; Sui Zhang; Donna Niedzwiecki; Fang-Shu Ou; I-Wen Chang; Bert H O'Neil; Federico Innocenti; Heinz-Josef Lenz; Charles D Blanke; Richard M Goldberg; Alan P Venook; Robert J Mayer; Charles S Fuchs
Journal:  Clin Cancer Res       Date:  2019-09-23       Impact factor: 12.531

8.  Vitamin D for Prevention and Treatment of Colorectal Cancer: What is the Evidence?

Authors:  Kimmie Ng
Journal:  Curr Colorectal Cancer Rep       Date:  2014-09-01

9.  Serum Total 25-Hydroxyvitamin D Levels in Patients With Cutaneous Malignant Melanoma: A Case-Control Study in a Low-Risk Southern European Population.

Authors:  Angeliki Befon; Alexander C Katoulis; Sofia Georgala; Andreas Katsampas; Vasiliki Chardalia; Aggeliki Melpidou; Vasiliki Tzanetakou; Vasiliki Chasapi; Dorothea Polydorou; Clio Desinioti; Micaela Plaka; Dimitris Rigopoulos; Alexandros J Stratigos
Journal:  Dermatol Pract Concept       Date:  2019-12-31

10.  Prospective study of predictors of vitamin D status and survival in patients with colorectal cancer.

Authors:  K Ng; B M Wolpin; J A Meyerhardt; K Wu; A T Chan; B W Hollis; E L Giovannucci; M J Stampfer; W C Willett; C S Fuchs
Journal:  Br J Cancer       Date:  2009-08-18       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.